within Pharmacolibrary.Drugs.C_CardiovascularSystem.C08E_NonSelectiveCalciumChannelBlockers.C08EA01_Fendiline;
model Fendiline 
   extends Pharmacolibrary.Drugs.ATC.C.C08EA01;

  annotation(Documentation(
    info ="<html><body><p>Fendiline is a non-selective calcium channel blocker, historically used as an antianginal and antiarrhythmic agent. Its clinical use is now largely discontinued and withdrawn in most countries due to lack of efficacy compared to more modern agents and potential adverse effects.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adults following oral administration; no human clinical PK data published.</p><h4>References</h4><ol><li><p>Weyhenmeyer, R, et al., &amp; Friedel, R (1987). Tolerance and pharmacokinetics of oral fendiline. <i>Arzneimittel-Forschung</i> 37(1) 58–62. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3566858/&quot;>https://pubmed.ncbi.nlm.nih.gov/3566858</a></p></li><li><p>Kukovetz, WR, et al., &amp; Mayer, D (1982). Single dose pharmacokinetics of fendiline in humans. <i>European journal of drug metabolism and pharmacokinetics</i> 7(2) 105–110. DOI:<a href=&quot;https://doi.org/10.1007/BF03188726&quot;>10.1007/BF03188726</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7117293/&quot;>https://pubmed.ncbi.nlm.nih.gov/7117293</a></p></li><li><p>Benthe, HF, &amp; Thieme, RA (1983). Identification of fendiline metabolites in human urine. <i>Biomedical mass spectrometry</i> 10(2) 65–73. DOI:<a href=&quot;https://doi.org/10.1002/bms.1200100204&quot;>10.1002/bms.1200100204</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6838997/&quot;>https://pubmed.ncbi.nlm.nih.gov/6838997</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Fendiline;
